Literature DB >> 6154964

Beta 2-microglobulin in chronic lymphocytic leukaemia.

B Simonsson, L Wibell, K Nilsson.   

Abstract

The serum level of beta 2-microglobulin (S-beta 2 m), a cell membrane protein associated with HLA-antigens, was quantitated in a series of 23 consecutive patients with chronic lymphocytic leukaemia (CLL). Markedly elevated values of S-beta 2 m (greater than 4.5 mg/1) were found in 10 patients, while only 3 patients had normal values (less than 3.0 mg/1). High serum values correlated with a large tumour mass, as estimated by Rai's clinical staging and by the total peripheral lymphocyte count. Blood lymphocyte proliferative activity, which has been suggested as reflecting disease activity in CLL, was measured by 3H-thymidine uptake in cells in vitro. The 3H-thymidine uptake was high in 3 patients all of whom were among the 5 patients with the highest S-beta 2m-values. S-beta 2m-determinations seem to be of definite interest in the study of patients with CLL although long term studies will be necessary for evaluation of the practical clinical value.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154964     DOI: 10.1111/j.1600-0609.1980.tb02364.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  12 in total

Review 1.  Soluble HLA revisited.

Authors:  William B Tabayoyong; Nicholas Zavazava
Journal:  Leuk Res       Date:  2006-07-24       Impact factor: 3.156

2.  Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages.

Authors:  Massimo Gentile; Giovanna Cutrona; Antonino Neri; Stefano Molica; Manlio Ferrarini; Fortunato Morabito
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

3.  Beta 2-microglobulin in haematological malignancies.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-28

4.  Mechanism and significance of abnormal blood level of beta 2-microglobulin in patients with Graves' disease.

Authors:  X L Han; W X Yie
Journal:  J Tongji Med Univ       Date:  1988

Review 5.  Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

Authors:  Paula Cramer; Michael Hallek
Journal:  Nat Rev Clin Oncol       Date:  2010-10-19       Impact factor: 66.675

6.  Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.

Authors:  B Hofmann; H Bass; P Nishanian; M Faisal; R A Figlin; G P Sarna; J L Fahey
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

7.  Serum beta 2-microglobulin, sialic acid, and C-reactive protein in systemic lupus erythematosus.

Authors:  C P Maury; T Helve; C Sjöblom
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

8.  Evaluation of Interleukin-9 Expression as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia in a Cohort of Egyptian Patients.

Authors:  Hadeer A Abbassy; Reham A Aboelwafa; Omar M Ghallab
Journal:  Indian J Hematol Blood Transfus       Date:  2017-03-17       Impact factor: 0.900

9.  Treatment of solid tumors should obligatorily be combined with the in vivo codepletion of tumor-protecting, CD8+/HLA-DR(+)-suppressor T cells by alloreactive donor T cells whose preprogrammed cell death allows a high GvL-effect before GvHD can be established. Results of animal experiments, including more than 6000 mice.

Authors:  P Leskovar; J Bielmeier
Journal:  Pflugers Arch       Date:  1996       Impact factor: 3.657

10.  β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.

Authors:  Philip A Thompson; Susan M O'Brien; Lianchun Xiao; Xuemei Wang; Jan A Burger; Nitin Jain; Alessandra Ferrajoli; Zeev Estrov; Michael J Keating; William G Wierda
Journal:  Cancer       Date:  2015-11-20       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.